A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers

Trial Profile

A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Trastuzumab
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-014; PANACEA
  • Most Recent Events

    • 09 Dec 2017 Trial design (phase Ib/II) and baseline characteristics of patients enrolled in phase II part, presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 09 Dec 2017 Results of phase Ib (n=6) assessing dose-limiting toxicities, presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 30 Nov 2017 According to a Merck AG media release, results from this trial will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top